Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Senior Management Personnel

 Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ms. Shikha Mirchandani Chatrath as Director - Commercial Excellence, BD & Strategy with effect from June 17, 2024,
01-06-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Please find the enclosed newspaper publication for the Postal Ballot Notice dated May 27, 2024.
31-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 We are enclosing herewith the Postal Ballot Notice dated May 27, 2024, being sent to the members of the Company to their registered email address, seeking approval of the members for the special business as set out therein.
31-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Please find the enclosed newspaper advertisement of the financial results of the Company for the quarter and year ended March 31, 2024 for your reference.
29-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 In terms of SEBI''s circular no. CIR/CFD/CMD1/27/2019 dated February 8, 2019, we furnish herewith the Secretarial Compliance Report, for the year ended March 31, 2024.
29-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed the press release for the audited financial results for the financial year ended March 31, 2024.
27-05-2024
Bigul

FY24 Annual Result Announced for AstraZeneca Pharma India Ltd.

 Pharmaceuticals company AstraZeneca Pharma India announced FY24 results: Revenue from Operations for FY24 stood at Rs 1,296 crore with substantial 29% increase. Profit Before Tax is Rs 220 crore registering a commendable 64% growth (PBT before exceptional items at Rs 201 crore, up by 17% compared to previous financial year). Earnings Per Share (EPS) for financial year stood at Rs 64.6 demonstrating a significant growth of 63% The Board of Directors, at its meeting dated May 27, 2024, have recommended a final dividend of Rs. 24 per equity share for FY24, subject to approval of shareholders at the Annual General Meeting of the Company. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " FY24 was one of the strongest years for us in the country and we take immense pride in our consistent performance. AstraZeneca India products sales for first time cross Rs 1000 crore mark, delivering total revenue of almost Rs ~1300 crore with growth of 29% this year. A successful execution of our growth through innovation strategy is helping us propel our ambition to be pioneers in science and lead in specialist disease areasin India. Science is guiding us, and our remarkable pipeline progress with 9 new medicines and indication approvals that we received last year, positions us optimally and we feel motivated to bring more innovative therapies faster and closer to patients in India. Our scientific progress and great support from different states, peers, and industry stakeholders positions us optimally to achieve our purpose of leaving no patients behind in the therapy areas we are present in and sustainably continue our strive to contribute to people, society, and the planet." Bhavana Agrawal, Chief Finance Officer, added, "Our strong full year performance is reflection of company’s focus on being a specialist organization & strong operational execution. This achievement reflects our relentless pursuit of identifying and capitalizing on opportunities in a dynamic environment. It underscores our dedication to not only achieving financial excellence but doing so in a sustainable and strategic manner." Result PDF
27-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Resignation of Director

 We wish to inform that Mr. Ankush Nandra, Non-Executive Director has resigned from the office of Director of the Company w.e.f. close of working hours on May 27, 2024.
27-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Monday, May 27, 2024

 The Board of Directors of the Company at its meeting held today i.e., May 27, 2024, has inter-alia: 1. Approved the Audited financial results of the Company for the quarter and year ended March 31, 2024. The said Audited financial results together with the Audit report of the Statutory Auditors dated May 27, 2024 are enclosed herewith. 2. Recommended Dividend of Rs. 24/- per equity share for the financial year 2023-24. We also confirm that the Statutory Auditor's Report is with unmodified opinion in respect of the Audited financial results of the Company for the financial year ended March 31, 2024.
27-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Dividend Updates

 We wish to inform that at the meeting of Board of Directors of the Company held on May 27, 2024, the Board has recommended dividend of Rs. 24/- per equity share of Rs. 2/- each subject to the approval of the shareholders at the forthcoming AGM of the Company.
27-05-2024
Next Page
Close

Let's Open Free Demat Account